ZEVRA THERAPEUTICS INC.

NASDAQ: ZVRA (Zevra Therapeutics, Inc.)

Last update: 2 days ago, 3:27AM

7.75

-0.20 (-2.52%)

Previous Close 7.95
Open 7.90
Volume 1,784,978
Avg. Volume (3M) 1,316,919
Market Cap 435,047,040
Price / Earnings (Forward) 10.10
Price / Sales 6.87
Price / Book 3.82
52 Weeks Range
6.19 (-20%) — 13.16 (69%)
Earnings Date 11 Nov 2025
Profit Margin -226.64%
Operating Margin (TTM) -26.28%
Diluted EPS (TTM) -1.94
Quarterly Revenue Growth (YOY) 495.70%
Total Debt/Equity (MRQ) 150.74%
Current Ratio (MRQ) 3.02
Operating Cash Flow (TTM) -61.72 M
Levered Free Cash Flow (TTM) -39.23 M
Return on Assets (TTM) -27.73%
Return on Equity (TTM) -204.78%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Zevra Therapeutics, Inc. Bullish Bullish

AIStockmoo Score

0.0
Analyst Consensus 5.0
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages -2.5
Technical Oscillators -0.5
Average 0.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ZVRA 435 M - - 3.82
PCVX 4 B - - 1.35
OCUL 2 B - - 7.29
IDYA 2 B - - 2.25
IRON 2 B - - 3.39
SRPT 2 B - - 1.33

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 0.69%
% Held by Institutions 65.42%

Ownership

Name Date Shares Held
Rubric Capital Management Lp 30 Jun 2025 1,958,318
Aigh Capital Management Llc 30 Jun 2025 918,893
Velan Capital Investment Management Lp 30 Jun 2025 715,000
52 Weeks Range
6.19 (-20%) — 13.16 (69%)
Price Target Range
18.00 (132%) — 29.00 (274%)
High 29.00 (Cantor Fitzgerald, 274.19%) Buy
Median 26.00 (235.48%)
Low 18.00 (JMP Securities, 132.26%) Buy
Average 24.33 (213.94%)
Total 3 Buy
Avg. Price @ Call 10.29
Firm Date Target Price Call Price @ Call
JMP Securities 13 Aug 2025 18.00 (132.26%) Buy 9.43
Cantor Fitzgerald 10 Jul 2025 29.00 (274.19%) Buy 12.02
HC Wainwright & Co. 02 Jul 2025 26.00 (235.48%) Buy 9.41

No data within this time range.

Date Type Details
04 Sep 2025 Announcement Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
28 Aug 2025 Announcement Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
26 Aug 2025 Announcement Zevra Therapeutics to Participate at Upcoming Investor Conferences in September
12 Aug 2025 Announcement Zevra Reports Second Quarter 2025 Financial Results and Corporate Update
06 Aug 2025 Announcement Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
04 Aug 2025 Announcement Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
28 Jul 2025 Announcement Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
18 Jul 2025 Announcement Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
16 Jul 2025 Announcement Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
11 Jul 2025 Announcement Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria